BLACK DIAMOND THERAPEUTICS I's ticker is BDTX and the CUSIP is 09203E105. A total of 102 filers reported holding BLACK DIAMOND THERAPEUTICS I in Q2 2021. The put-call ratio across all filers is 1.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,874 | -43.2% | 2,046,517 | 0.0% | 0.25% | -21.2% |
| Q2 2023 | $10,335 | +232.1% | 2,046,517 | +24.3% | 0.32% | +73.0% |
| Q1 2023 | $3,112 | +5.0% | 1,646,517 | 0.0% | 0.18% | +12.1% |
| Q4 2022 | $2,964 | -99.9% | 1,646,517 | 0.0% | 0.16% | +38.7% |
| Q3 2022 | $2,783,000 | -31.3% | 1,646,517 | 0.0% | 0.12% | -44.9% |
| Q2 2022 | $4,050,000 | -11.2% | 1,646,517 | 0.0% | 0.22% | +13.1% |
| Q1 2022 | $4,561,000 | -48.0% | 1,646,517 | 0.0% | 0.19% | -19.7% |
| Q4 2021 | $8,776,000 | -37.0% | 1,646,517 | 0.0% | 0.24% | -23.7% |
| Q3 2021 | $13,930,000 | -30.6% | 1,646,517 | 0.0% | 0.31% | -23.3% |
| Q2 2021 | $20,071,000 | -49.8% | 1,646,517 | 0.0% | 0.41% | -42.4% |
| Q1 2021 | $39,945,000 | -24.3% | 1,646,517 | 0.0% | 0.71% | -37.7% |
| Q4 2020 | $52,771,000 | +14.7% | 1,646,517 | +8.2% | 1.13% | +1.4% |
| Q3 2020 | $45,995,000 | -29.5% | 1,521,517 | -1.6% | 1.12% | -38.8% |
| Q2 2020 | $65,201,000 | +54.0% | 1,546,517 | -8.8% | 1.82% | +2.0% |
| Q1 2020 | $42,328,000 | – | 1,696,517 | – | 1.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 3,449,845 | $5,830,000 | 0.29% |
| K2 PRINCIPAL FUND, L.P. | 1,031,511 | $1,743,000 | 0.20% |
| Boxer Capital, LLC | 2,014,858 | $3,405,000 | 0.19% |
| DAFNA Capital Management LLC | 313,600 | $530,000 | 0.14% |
| Newtyn Management, LLC | 350,000 | $592,000 | 0.13% |
| Artal Group S.A. | 1,646,517 | $2,783,000 | 0.12% |
| Bellevue Group AG | 4,717,113 | $7,972,000 | 0.11% |
| MPM BioImpact LLC | 239,888 | $405,000 | 0.10% |
| RA Capital Management | 2,589,904 | $4,377,000 | 0.09% |
| Beacon Capital Management, LLC | 35,615 | $88,000 | 0.03% |